Genflow Biosciences PLC Announces Holding(s) in Company – 2
Genflow Biosciences PLC Announces Holding(s) in Company – 1
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025
MaryRuth’s Celebrates TikTok Shop Super Brand Day With Exclusive Offers and Viral Favorites
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Top-line Data Now Anticipated in Q1 2025 LX9211 has previously received Fast Track designation from the U.S. Food and Drug...
LAFAYETTE, La., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in...
Two Additional Clinical Sites to be Opened in the United Kingdom Both Sites are Recognized Centers of Excellence for Netherton...
GARDEN CITY, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next...
DENVER, Oct. 22, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in...
Agreement reinforces Scorpius' position as a respected U.S. biomanufacturing partner for early-stage and clinical developmentDURHAM, N.C., Oct. 22, 2024 (GLOBE NEWSWIRE)...
Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseasesThe newly published...
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate...
Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA nephropathyAdditional oral...
PURCHASE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company...
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader...
Late-breaking oral presentation to highlight safety and efficacy of LX1001 across four dose cohortsNEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE)...
Serial entrepreneur and medical device industry executive adds key experience to board of directorsPARIS, Oct. 22, 2024 (GLOBE NEWSWIRE) --...
- CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD - - Differentiated Profile for...
Determined the high dose of OCU410ST to be the maximum tolerated doseNo serious adverse events have been reportedApproved proceeding to...
STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe...
Nodenza Venture Partners invests in Trellis Bioscience Lead product TRL1068 targets biofilm, estimated to cause 60-70% of antibiotic resistant infections...
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults...
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults...
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults...
